Shares Of Chimerix Higher By Nearly 6% After Point72 Stake Reveal

Shares of Chimerix Inc CMRX, a biopharmaceutical company that develops and commercializes oral antivirals, surged higher by nearly 6 percent early Thursday morning after Point72 Asset Management disclosed a 5.3 percent stake in the company. Shares of Chimerix plunged more than 80 percent on Monday. Steve Cohen's Point72 Asset Management reported owning more than 2.45 million shares in the biotechnology company. CNBC noted that It is unclear if the purchase was made prior to or after Monday's plunge in Chimerix's stock.